Global Human Coagulation Factor VIII Market Growth 2023-2029
Human Coagulation Factor VIII is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene, defects in this gene results in hemophilia A. Human Coagulation Factor VIII concentrated from donated blood plasma (Aafact or Alphanate, Monoclate-P®), or alternatively recombinant Human Coagulation Factor VIII can be given to hemophiliacs to restore hemostasis.
LPI (LP Information)' newest research report, the “Human Coagulation Factor VIII Industry Forecast” looks at past sales and reviews total world Human Coagulation Factor VIII sales in 2022, providing a comprehensive analysis by region and market sector of projected Human Coagulation Factor VIII sales for 2023 through 2029. With Human Coagulation Factor VIII sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Human Coagulation Factor VIII industry.
This Insight Report provides a comprehensive analysis of the global Human Coagulation Factor VIII landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Human Coagulation Factor VIII portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Human Coagulation Factor VIII market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Coagulation Factor VIII and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Coagulation Factor VIII.
The global Human Coagulation Factor VIII market size is projected to grow from US$ 10010 million in 2022 to US$ 15590 million in 2029; it is expected to grow at a CAGR of 15590 from 2023 to 2029.
Global Human Coagulation Factor VIII key players include Baxter, Bayer, CSL, Pfizer, Biogen, etc. Global top five manufacturers hold a share about 80%. North America is the largest market, with a share about 60%, followed by Europe, with a share about 30 percent. In terms of product, Recombinant Factor VIII is the largest segment, with a share about 65%. And in terms of application, the largest application is Hemophilia A, followed by Spontanous / Trauma, Surgical, etc.
This report presents a comprehensive overview, market shares, and growth opportunities of Human Coagulation Factor VIII market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Recombinant Factor VIII
Plasma-derived Factor VIII
Segmentation by application
Hemophilia A
Spontanous / Trauma
Surgical
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Shire (Baxter)
Bayer
CSL
Pfizer
Grifols
Biogen
Octapharma
NovoNordisk
Greencross
Kedrion
BPL
Hualan Bio
RAAS
Key Questions Addressed in this Report
What is the 10-year outlook for the global Human Coagulation Factor VIII market?
What factors are driving Human Coagulation Factor VIII market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Human Coagulation Factor VIII market opportunities vary by end market size?
How does Human Coagulation Factor VIII break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Please note: The report will take approximately 2 business days to prepare and deliver.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook